# 2023 ESMO GYNAECOLOGICAL CANCERS

Annual Congress

BARCELONA SPAIN
23-24 FEBRUARY 2023

# **KNOWN**

- Utility of Serum CA19-9 level is in diagnostic workup of mucinous tumors
- Marker of poor prognosis and unresectability in pancreato-billiary cancers

### **LACUNAE**

- Role in EOC- UNKNOWN
- Association with CA 125 AND CEA-UNKNOWN


### **OBJECTIVE**

To
prognosticate
CA19 9 levels
in EOC and corelate with
survival.

### **METHODS**

- Retrospective study
- Duration-September 2019 to December 2021.
- Definition of increased CA 19-9
   levels > 37 mIU/mL were considered
   as cut off levels.
- Study done according to REMARK guidelines

### **RESULTS**



# Redefining the role of CA 19-9 as a prognostic marker in Epithelial Ovarian Cancer

Eshwarya J Kaur, Upasana Baruah, Debabrata Barmon, Dimpy Begum Dr B Borooah Cancer Institute, Guwahati , A unit of DAE and TMH, Mumbai

## **PREDICTIVE**

Higher Risk of Malignancy (ROM) with raised levels of CA 19-9 (RR-2.78)

# **DIAGNOSTIC- KRUKENBERG**

- 31.8% Krukenberg patients- Normal CEA levels with raised CA 19-9 levels
- Only 45.45% Krukenberg patients had CA 125:CEA ratio <25</li>
- Higher chances of Krukenberg (68.2%) with concurrently raised CA 19-9 and CEA levels

# DIAGNOSTIC- EOC

- Higher incidence of HGSOC than Mucinous CA with raised levels (36.7% vs 13.2%)
- Levels independent from CA 125 (Pearson's r = -.133)

## **PROGNOSTIC**

 26.4% Patients with raised CA 19-9 had platinum refractory disease vs 14.7% with normal CA 19-9 levels




Fig 1. Comparison of surgical outcomes




Fig 2. OS significantly lower, (p=0.008) in EOC with raised CA 19-9 levels.

# FNP number 63P



CA 19-9 LEVELS	Median RFS in months (95% CI)	Mean OS in months (95% CI)
< 37 U/ml	15.0 (11.083-18.917)	47.127 (37.862-56.392)
>37 U/ml	12.0 (7.406- 16.594)	32.816 (23.855- 41.776)

Table1. Survival outcomes in patients with raised CA 19.9 levels

# WHAT THIS RESEARCH ADDS?



HIGHER ROM

HIGHER RATES OF PROGRESSIVE DS

HIGHER RATES OF PLATINUM RESISTANCE

This novel finding is previously unreported in literature

### **BIBLIOGRAPHY**

- 1. Hatzaras, I., Schmidt, C., Muscarella, P., Melvin, W.S., Ellison, E.C. and Bloomston, M., 2010. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. Hpb, 12(2), pp.134-138.
- 2. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia. 2003 Dec;58(5):667-72. PMID: 15190651.
- 3. Stenman UH, Alfthan H, Vartiainen J, Lehtovirta P. Markers supplementing CA 125 in ovarian cancer. Annals of medicine. 1995 Jan 1;27(1):115-20.

### **Conflicts of interest- None to declare**